Corient Private Wealth LP Boosts Holdings in Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Corient Private Wealth increased its Amneal Pharmaceuticals stake by 1,254% in the second quarter, bringing its holdings to 150,698 shares valued at approximately $2.6 million. Other institutional investors also added positions, while institutions collectively own 31.82% of the company.
• Amneal shares opened at $20.16, up 7.7%, near their 12-month high of $21.18. The company exceeded quarterly earnings expectations, reporting $0.30 per share versus the $0.24 consensus estimate on revenue of $796.2 million.
• Analyst sentiment remains favorable, with eight Buy ratings and one Hold rating, producing a consensus “Moderate Buy” rating and a $20.14 target price. However, insiders sold 413,016 shares worth about $7.2 million over the past three months.

Corient Private Wealth LP grew its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 1,254.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 150,698 shares of the company's stock after purchasing an additional 139,568 shares during the quarter. Corient Private Wealth LP's holdings in Amneal Pharmaceuticals were worth $2,609,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in Amneal Pharmaceuticals in the 2nd quarter valued at $180,000. Paralel Advisors LLC purchased a new stake in shares of Amneal Pharmaceuticals during the second quarter worth $3,217,000. Odyssean LLC raised its position in shares of Amneal Pharmaceuticals by 62.5% in the second quarter. Odyssean LLC now owns 183,507 shares of the company's stock valued at $3,177,000 after buying an additional 70,589 shares during the last quarter. RPg Family Wealth Advisory LLC lifted its stake in shares of Amneal Pharmaceuticals by 88.5% in the second quarter. RPg Family Wealth Advisory LLC now owns 377,090 shares of the company's stock worth $6,527,000 after buying an additional 176,998 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in Amneal Pharmaceuticals during the second quarter worth about $29,000. Hedge funds and other institutional investors own 31.82% of the company's stock.

Insider Buying and Selling

In other news, Director John Kiely sold 50,000 shares of Amneal Pharmaceuticals stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $17.64, for a total transaction of $882,000.00. Following the completion of the sale, the director directly owned 210,252 shares in the company, valued at $3,708,845.28. The trade was a 19.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Nikita Shah sold 146,403 shares of the company's stock in a transaction dated Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the sale, the executive vice president owned 253,390 shares of the company's stock, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 413,016 shares of company stock worth $7,216,567 in the last three months. Corporate insiders own 17.30% of the company's stock.

Amneal Pharmaceuticals Trading Up 7.7%

NASDAQ:AMRX opened at $20.16 on Tuesday. Amneal Pharmaceuticals, Inc. has a 12-month low of $9.49 and a 12-month high of $21.18. The firm has a market cap of $6.44 billion, a PE ratio of 41.14 and a beta of 1.24. The company has a current ratio of 2.20, a quick ratio of 1.44 and a debt-to-equity ratio of 77.65. The stock has a fifty day moving average price of $17.90 and a 200 day moving average price of $15.22.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Thursday, July 30th. The company reported $0.30 earnings per share for the quarter, beating the consensus estimate of $0.24 by $0.06. Amneal Pharmaceuticals had a net margin of 5.05% and a negative return on equity of 584.46%. The firm had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. Sell-side analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.94 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Zacks Research lowered Amneal Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 7th. Wall Street Zen raised Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Sunday, July 12th. The Goldman Sachs Group reissued a "buy" rating and issued a $21.00 price objective on shares of Amneal Pharmaceuticals in a report on Friday, July 31st. Weiss Ratings upgraded shares of Amneal Pharmaceuticals from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Wednesday, August 26th. Finally, Barclays lifted their target price on shares of Amneal Pharmaceuticals from $16.00 to $20.00 and gave the stock an "overweight" rating in a research note on Thursday. Eight equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $20.14.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include dosage forms such as tablets, capsules, injectables, ophthalmic products and inhalation therapies, with a focus on complex generics and other products that can be more difficult to develop or manufacture.

The company also markets branded specialty pharmaceuticals in areas including central nervous system disorders, endocrinology, metabolic disease and other therapeutic categories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.